Free Trial
NYSEAMERICAN:VNRX

VolitionRx (VNRX) Stock Price, News & Analysis

VolitionRx logo
$0.56
-0.05 (-8.20%)
(As of 10/31/2024 ET)

About VolitionRx Stock (NYSEAMERICAN:VNRX)

Key Stats

Today's Range
$0.55
$0.61
50-Day Range
N/A
52-Week Range
$0.43
$1.23
Volume
291,323 shs
Average Volume
162,152 shs
Market Capitalization
$35.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

Receive VNRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VolitionRx and its competitors with MarketBeat's FREE daily newsletter.

VNRX Stock News Headlines

Q2 2024 VolitionRX Ltd Earnings Call Transcript
Election warning coming true…
If you missed it, my emergency election broadcast is now available - watch it before it's too late.
VNRX Stock Earnings: VolitionRX Beats EPS, Misses Revenue for Q2 2024
VolitionRX earnings preview: what Wall Street is expecting
See More Headlines

VNRX Stock Analysis - Frequently Asked Questions

VolitionRx Limited (NYSEAMERICAN:VNRX) posted its quarterly earnings data on Wednesday, August, 14th. The medical research company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.01. The medical research company earned $0.40 million during the quarter, compared to analyst estimates of $0.34 million. VolitionRx had a negative net margin of 9,158.31% and a negative trailing twelve-month return on equity of 15,493.47%.

Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that VolitionRx investors own include Chesapeake Energy (CHKAQ), Bausch Health Companies (BHC), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Exelixis (EXEL), T2 Biosystems (TTOO) and Gilead Sciences (GILD).

Company Calendar

Last Earnings
8/14/2024
Today
10/31/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSEAMERICAN:VNRX
Previous Symbol
NYSEMKT:VNRX
CIK
N/A
Employees
80
Year Founded
N/A

Profitability

Net Income
$-30,270,000.00
Net Margins
-9,158.31%
Pretax Margin
-9,257.43%
Return on Equity
-15,493.47%

Debt

Sales & Book Value

Annual Sales
$310,000.00
Book Value
($0.05) per share

Miscellaneous

Free Float
53,450,000
Market Cap
$38.35 million
Optionable
Not Optionable
Beta
1.59
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (NYSEAMERICAN:VNRX) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners